Evidence map›Paper›PMID 30453928›Full record

ArticleBMC ophthalmology2018

Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.

Haihong Yuan, Hui Li, Ping Yu, Qichen Fan, Xuan Zhang, Wei Huang, Junyi Shen, Yongyao Cui, Wei Zhou

Open access · goldAbstract read
In one paragraph

Article in BMC ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Dysregulation of histone deacetylases in ocular diseases.Archives of pharmacal research · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Haihong YuanDepartment of Pharmacy, Shanghai University of Medicine & Health Science, Shanghai, China.
Hui LiDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Ping YuDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Qichen FanDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Xuan ZhangDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Wei HuangDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Junyi ShenDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
Yongyao CuiDepartment of Pharmacology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China. yongyaocui@hotmail.com.
Wei ZhouLaboratory of Oral Microbiota and Systemic Diseases, Shanghai Research Institute of Stomatology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 115 Jin Zun Road, Shanghai, 200125, China. sweetzw@hotmail.com.
Shanghai Jiao Tong University · CNShanghai University of Medicine and Health Sciences · CNZhongshan Hospital · CN

Funding

National Science and Technology Major Projects for Major New Innovation and Development 2014ZX09104002005the National Natural Science Foundation of China 81273519, 30700280the National Natural Science Foundation of China 81370144the Shanghai Education Commission 12YZ037the Shanghai Education Commission 12YZ200
6 · The paper itself

Abstract

backgroundThe role of histone deacetylases 6 (HDAC6) has been elucidated in various neurodegenerative diseases. However, the effect of HDAC6 on retinal degenerative processes remains unknown. The aim of this study was to elucidate the potential role of HDAC6 in the retinal ischaemia and reperfusion (I/R) injury model.

methodsThe retinal pathological lesion was evaluated by haematoxylin and eosin (H&E) staining. HDAC expression or activity was detected by immunohistochemistry, Western blotting assays or colorimetric assays. The expression of apoptotic- and autophagic- related proteins were quantified by Western blotting and RT-PCR. The expression of peroxiredoxin 2 (Prx2) was determined by RT-PCR and ELISA. The levels of acetylated α-tubulin and acetylated histone 3 in the retina were assayed by Western blotting.

resultsWe found that I/R-induced reduction of the retinal thickness was ameliorated, and the survival of RGCs was increased by the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) as well as by tubacin (an HDAC6 selective inhibitor). The decreased expression of THY (thymus cell antigen) in the I/R-induced retinas was also reversed by TSA and tubacin. Elevated HDAC6 expression and activity in the retina from I/R injury were significantly inhibited by tubacin, which also attenuated I/R-mediated apoptosis by decreasing TUNEL-positive RGCs and Bax expression and increasing Bcl-2 expression. Additionally, tubacin increased the expression of autophagy-related gene Beclin 1 and microtubule-associated protein 1 light chain 3B (LC3B) and the levels of Prx2. Furthermore, the protective effect of tubacin was associated with acetylated α-tubulin and was independent of acetylated histone 3.

conclusionsOur findings suggest that tubacin exhibits neuroprotective effects after I/R retinal injury, and HDAC6 may be a potential therapeutic target for the retinal neurodegenerative disease of glaucoma.

Indexed as

AnilidesAnimalsBlotting, WesternDisease Models, AnimalHistone Deacetylase 6Histone Deacetylase InhibitorsHomeodomain ProteinsHydroxamic AcidsImmunohistochemistryIschemiaNeuroprotective AgentsRatsRetinaRetinal DegenerationTranscription FactorsAnilidesHDAC6 protein, ratHistone Deacetylase 6Histone Deacetylase InhibitorsHomeodomain ProteinsHydroxamic AcidsNeuroprotective AgentsPrrx2 protein, ratTranscription FactorstubacinGlaucomaHDAC6Ischaemia and reperfusionNeuroprotectionTubacin

Identifiers

PMID30453928
PMCPMC6245782
OpenAlexW2901521097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.